“
“Polymorphisms in adipokine genes, such as leptin (LEP), leptin receptor (LEPR), resistin (RETN), adiponectin (ADIPOQ), interleukin-1 beta (IL-1 beta), IL-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) may be involved in the development of obesity. We conducted
a systematic review of published evidence on the association between different adipokine genes and the risk of obesity. Librarian-designed searches of PubMed and HuGeNet, review of reference lists from published reviews and content expert advice identified potentially eligible studies. The genotyping information and polymorphisms of different adipokine genes, numbers of genotyped cases and controls and frequencies of genotypes were extracted from 48 eligible studies included in this review. Twenty-one Stem Cell Compound Library ic50 polymorphisms each associated with obesity in at least one study were identified. Polymorphisms in the adipokine genes, LEP, LEPR, and HSP990 RETN were not associated with obesity susceptibility, whereas ADIPOQ G276T (T vs. G: odds ratio (OR), 1.59; 95% confidence interval (Cl), 1.39-1.81), IL-1 beta C3953T (CC vs. CT+TT: OR, 1.61; 95% Cl, 1.18-2.20), and TNF-alpha G308A (GG vs. GA+AA: OR, 1.19; 95% Cl, 1.02-1.39) polymorphisms were associated with an increased
risk of obesity. The IL-6 G174C polymorphism was also associated obesity when using allelic comparisons, the recessive genetic model and the dominant genetic model with OR (95% Cl) of 1.95 (1.37-2.77), 1.44 (1.15-1.80), and 1.36 (1.16-1.59), respectively. No significant evidence of publication bias was present. However, these “null” results were underpowered due to a small pooled sample size, and analysis of additional case control studies with larger sample sizes should provide further clarifications.”
“Background:\n\nLack of response
in some patients and relapse during the course of therapy in the treatment of HER2-positive early breast cancer and metastatic breast cancer continue to challenge researchers and clinicians towards a better understanding of the fundamental mechanisms of trastuzumab action and new therapies for HER2. The aim of this review is to discuss current and future treatment options Volasertib with pertuzumab in the light of new insights into HER2-positive breast cancer.\n\nScope:\n\nPertuzumab showed positive results in clinical studies and agents in routine clinical usage are updated. The PubMed database, ASCO and San Antonio Breast Cancer Symposium Meeting abstracts were searched up to June 2012 by using the terms ‘pertuzumab’ and ‘anti-HER2 treatment’; papers which were considered relevant for the aim of this review were selected by the authors.\n\nFindings:\n\nThe presented trials of phase II and phase III randomized trials of CLEOPATRA, NEOSPHERE and TRYPHAENA have showed pertuzumab action to be complementary to trastuzumab without increasing adverse events.